Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingNot a traditional drug phaseobservationalRules rewrite

Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants

This study will provide follow-up evaluation and care of patients who have undergone allogeneic (donor) stem cell transplantation at the NIH Clinical Center. Patients are monitored for their response to treatment, disease relapse, and later-occurring effects of the transplant.

Official registry: https://clinicaltrials.gov/study/NCT00106925 · National Heart, Lung, and Blood Institute (NHLBI) · enrollment listed as 1,000

What this phase means

This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.

They plan to enroll about 1,000 people at Bethesda. Taking part typically means study visits and measurements plus check-ins.

Official title (unrewritten)

Long-Term Evaluation and Follow Up Care of Patients Treated With Allogeneic Stem Cell Transplants

Primary outcome (registry wording): Assure consistency of care over time for transplant patients such that outcome data can be meaningfully accrued.

Who it is for (from inclusion criteria)

  • Ages 7 Years to 80 Years
  • TRANSPLANT RECIPIENTS:
  • Patients surviving three years or more from date of first stem cell transplant who have been treated
  • With an experimental allogeneic stem cell transplant on a NHLBI HB protocol
  • With a standard of care allogeneic stem cell transplant on an NHLBI protocol
  • Selectively, when the allogenic transplant was conducted outside the NIH, but the subject has a special condition of interest to the research team
  • Age greater than or equal to 7 years old and age less than or equal to 80

Public study contact (from the registry)

Bretagne C Cowling, R.N.

(301) 827-3479

bretagne.cowling@nih.gov

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBethesda, Maryland
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocy…

Background The development of new technologies now allow scientists to investigate the molecular basis and clinical manifestations of monoclonal B cell lymphocytosis (MBL), chronic lymphocytic leukemia(CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom macroglobulinemia (WM), and splenic marginal zone lymphoma (SMZL). Applying these methods in a natural history study can help identify processes involved in disease progression, and possibly lead to the discovery or validation of treatment targets.

NCT00923507 · Official ClinicalTrials.gov record · National Heart, Lung, and Blood Institute (NHLBI)

RecruitingPhase 2Houston, Texas
Phase 2: testing Blinatumomab for B Acute Lymphoblastic Leukemia

This phase II trial studies how well blinatumomab, inotuzumab ozogamicin, and combination chemotherapy work as frontline therapy in treating patients with B acute lymphoblastic leukemia. Immunotherapy with monoclonal antibodies, such as blinatumomab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread.

NCT02877303 · Official ClinicalTrials.gov record · M.D. Anderson Cancer Center

FAQ about this NCT record

Is NCT00106925 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT00106925?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT00106925?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary